title: The effect of ethyl pyruvate supplementation on rat fatty liver induced by a high-fat diet.
abstract: Continuous positive energy imbalance leads to obesity, which increases the risk of developing non-alcoholic fatty liver disease. The hepatoprotective effect of ethyl pyruvate has been revealed in several studies. Therefore, we examined the effect of ethyl pyruvate supplementation on liver cell damage, metabolism, membrane fluidity, and oxidative stress markers in rats fed a high-fat diet. After 6-wk feeding of a control or high-fat diet, Wistar rats were divided into 4 groups: control diet, control diet and ethyl pyruvate, high-fat diet, and high-fat diet and ethyl pyruvate. Ethyl pyruvate was administered as a 0.3% solution in drinking water, for the following 6 wk. Ethyl pyruvate intake attenuated the increase in activities of plasma transaminases and liver TNF-α. However, the supplementation was without effect in the lipid profiles, membrane fluidity or oxidative metabolism in liver induced by the high-fat diet. Our data confirm the potency of ethyl pyruvate against cell liver damage. Nevertheless, prolonged intake did not affect the development of a fatty liver.
authors.affiliation: Biochemistry Department, Gdansk University of Physical Education and Sport, Poland. robol@awf.gda.pl
authors.forename: Robert Antoni
authors.initials: RA
authors.lastname: Olek
authors.forename: Wieslaw
authors.initials: W
authors.lastname: Ziolkowski
authors.forename: Damian Jozef
authors.initials: DJ
authors.lastname: Flis
authors.forename: Donatella
authors.initials: D
authors.lastname: Fedeli
authors.forename: Dennis
authors.initials: D
authors.lastname: Fiorini
authors.forename: Tomasz Henryk
authors.initials: TH
authors.lastname: Wierzba
authors.forename: Rosita
authors.initials: R
authors.lastname: Gabbianelli
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D002462:Cell Membrane / Q000187:drug effects; D004041:Dietary Fats / Q000009:adverse effects*; D019587:Dietary Supplements; D005234:Fatty Liver / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D050356:Lipid Metabolism / Q000187:drug effects; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D065626:Non-alcoholic Fatty Liver Disease; D009765:Obesity / Q000150:complications; D018384:Oxidative Stress / Q000187:drug effects; D011773:Pyruvates / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D000637:Transaminases / Q000097:blood*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D004041:Dietary Fats; D011773:Pyruvates; D014409:Tumor Necrosis Factor-alpha; C046522:ethyl pyruvate; D000637:Transaminases